Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.35 |
| ▸ | GPR4 | P46093 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4939031 | 0.84 | REN (0.44) | — | |
| SCHEMBL4598388 | 0.83 | ADORA1 (0.34) | NR1H2RORCADORA1GPR119KDM4E | |
| SCHEMBL4941222 | 0.80 | NR1H2 (0.43) | NR1H2CYP4A11CYP4F2RORCGPR119 | |
| SCHEMBL19176107 | 0.80 | CHRM5 (0.45) | NR1H2ADORA1 | |
| SCHEMBL4941012 | 0.79 | NR1H2 (0.43) | NR1H2CYP4A11CYP4F2RORCGPR119 | |
| SCHEMBL4941015 | 0.73 | REN (0.44) | — | |
| SCHEMBL19168831 | 0.73 | CHRM5 (0.46) | ADORA1 | |
| SCHEMBL4598109 | 0.71 | TACR1 (0.35) | NR1H2RORCGPR119 | |
| SCHEMBL5274358 | 0.70 | NR1H2 (0.45) | NR1H2CYP4A11CYP4F2GPR119 | |
| SCHEMBL28760411 | 0.70 | NR1H2 (0.43) | NR1H2CYP4A11CYP4F2GPR119PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234305-A1 | Novel Tetrahydropyridine Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234305-A1 | Novel Tetrahydropyridine Derivatives | REN, AGTR1, CBR1 | NR1H2 797/4885CYP4A11 306/4885CYP4F2 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.